IOL Chemicals IOL Chemicals

X

Find the latest Drugs in Development and Pipeline Prospector News of Orion Corporation.

  • Webinars & Exhibitions

PharmaCompass
Fermion
Orion Corporation
Finland Flag
Country
Country
Finland
Address
Address
Head officeOrion CorporationOrionintie 1A, FI-02200 Espoo, FinlandP.O.Box 65, FI-02101 Espoo, Finland
Telephone
Telephone
+358 10 4261
Twitter
Twitter
Contact Info
Others

Details:

The net proceeds will be used to advance Lego's ADC pipeline including, LCB14, an antibody-drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2).


Lead Product(s): LCB14

Therapeutic Area: Oncology Product Name: LCB14

Highest Development Status: Phase IIIProduct Type: Large molecule

Recipient: LegoChem Biosciences

Deal Size: $410.9 million Upfront Cash: Undisclosed

Deal Type: Financing January 16, 2024

Fermion Orion Company Banner

euroPLX 84 Lisbon

Not Confirmed

envelop Contact Supplier

Details:

Under the agreement, Orion gains access to Glykos’ proprietary ADC technologies, initiating an ADC program and will be responsible for the target selection, research, development, and commercialization of up to three next-generation ADCs, with a focus on solid tumors.


Lead Product(s): Undisclosed

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Discovery PlatformProduct Type: Large molecule

Recipient: Glykos

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement January 08, 2024

Fermion Orion Company Banner

euroPLX 84 Lisbon

Not Confirmed

envelop Contact Supplier

Details:

ODM-208/MK5684 is an investigational CYP11A1 inhibitor, which is being evaluated in combination with hormone replacement therapy under phase 3 clinical trials for the treatment of metastatic castration-resistant prostate cancer (mCRPC).


Lead Product(s): MK5684,Dexamethasone,Fludrocortisone Acetate

Therapeutic Area: Oncology Product Name: ODM-208

Highest Development Status: Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Merck & Co

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 05, 2024

Fermion Orion Company Banner

euroPLX 84 Lisbon

Not Confirmed

envelop Contact Supplier

Details:

The agreement aims for the exclusive right to package, distribute, market and sell Suvexx, a patent protected, fixed dose combination of naproxen sodium and sumatriptan approved for the acute treatment of migraine attacks in adults, in all remaining E.U. countries.


Lead Product(s): Naproxen Sodium,Sumatriptan

Therapeutic Area: Neurology Product Name: Suvexx

Highest Development Status: ApprovedProduct Type: Small molecule

Recipient: Nuvo Pharmaceuticals

Deal Size: $0.6 million Upfront Cash: Undisclosed

Deal Type: Licensing Agreement August 15, 2023

Fermion Orion Company Banner

euroPLX 84 Lisbon

Not Confirmed

envelop Contact Supplier

Details:

Ztalmy (ganaxolone) is a positive allosteric modulation of the gamma-aminobutyric acid type A (GABAA) receptor in the CNS. It is used for the treatment of epileptic seizures associated with CDKL5 deficiency disorder.


Lead Product(s): Ganaxolone

Therapeutic Area: Genetic Disease Product Name: Ztalmy

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Marinus Pharmaceuticals

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 31, 2023

Fermion Orion Company Banner

euroPLX 84 Lisbon

Not Confirmed

envelop Contact Supplier

Details:

Nubeqa (darolutamide) is an oral androgen receptor inhibitor (ARi) with a distinct chemical structure that binds to the receptor with high affinity and exhibits strong antagonistic activity, thereby inhibiting the receptor function and the growth of prostate cancer cells.


Lead Product(s): Darolutamide,Docetaxel

Therapeutic Area: Oncology Product Name: Nubeqa

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Bayer AG

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 23, 2023

Fermion Orion Company Banner

euroPLX 84 Lisbon

Not Confirmed

envelop Contact Supplier

Details:

Nubeqa (darolutamide) is an oral androgen receptor inhibitor (ARi) with a distinct chemical structure that binds to the receptor with high affinity and exhibits strong antagonistic activity, thereby inhibiting the receptor function and the growth of prostate cancer cells.


Lead Product(s): Darolutamide,Docetaxel

Therapeutic Area: Oncology Product Name: Nubeqa

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 20, 2023

Fermion Orion Company Banner

euroPLX 84 Lisbon

Not Confirmed

envelop Contact Supplier

Details:

Nubeqa (darolutamide) is an oral androgen receptor inhibitor (ARi) with a distinct chemical structure that binds to the receptor with high affinity and exhibits strong antagonistic activity, thereby inhibiting the receptor function and the growth of prostate cancer cells.


Lead Product(s): Darolutamide,Docetaxel

Therapeutic Area: Oncology Product Name: Nubeqa

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 01, 2023

Fermion Orion Company Banner

euroPLX 84 Lisbon

Not Confirmed

envelop Contact Supplier

Details:

Nubeqa (darolutamide) is an oral androgen receptor inhibitor (ARi) with a distinct chemical structure that binds to the receptor with high affinity and exhibits strong antagonistic activity, thereby inhibiting the receptor function and the growth of prostate cancer cells.


Lead Product(s): Darolutamide,Docetaxel

Therapeutic Area: Oncology Product Name: Nubeqa

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Bayer AG

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 27, 2023

Fermion Orion Company Banner

euroPLX 84 Lisbon

Not Confirmed

envelop Contact Supplier

Details:

Nubeqa (darolutamide) is an oral androgen receptor inhibitor (ARi) with a distinct chemical structure that binds to the receptor with high affinity and exhibits strong antagonistic activity, thereby inhibiting the receptor function and the growth of prostate cancer cells.


Lead Product(s): Darolutamide,Docetaxel

Therapeutic Area: Oncology Product Name: Nubeqa

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 27, 2023

Fermion Orion Company Banner

euroPLX 84 Lisbon

Not Confirmed

envelop Contact Supplier
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY